Cellumen Establishes Collaboration in Breast Cancer Patient Stratification
Complete the form below to unlock access to ALL audio articles.
Cellumen, Inc. and Mayo Foundation for Medical Education and Research announced the formation of a collaboration to apply cellular systems biology (CSB™) profiling to breast cancer patient stratification. The goal is to create a breast cancer patient profile test to improve diagnosis and treatment for individualized medicine.
“We are very pleased to initiate an exciting research and development program with Mayo, a leader in individualized medicine,” stated D. Lansing Taylor, Ph.D, CEO of Cellumen. “We are treating breast tumors as a “system” within the breast cancer patient.
A combination of breast cancer biomarkers and migratory immune cell biomarkers are being multiplexed in tissue micro-array (TMA) samples.
“We are enthusiastic about the synergy between Cellumen and Mayo in approaching this challenging opportunity,” stated Taylor, “Mayo has great expertise and experience that will be applied to this collaboration. Cellumen continues to develop collaborations with the best in class partners to bring CSB solutions to the market.”
